IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates. read more
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
Read Also
- IDH to hold 2-day flagship event SUTRA from October 17
- Govt to release buffer stock in wholesale markets to control onion prices
- The US election has witnessed more political violence, just how ugly could it get?
- Evaluating TD Synnex: Insights From 7 Financial Analysts
- Here's How Much $100 Invested In Marathon Petroleum 10 Years Ago Would Be Worth Today
- Here's How Much $100 Invested In Marathon Petroleum 10 Years Ago Would Be Worth Today
- A Closer Look at 8 Analyst Recommendations For Crown Castle
- Your Digital Vault Awaits—1TB of Cloud Storage for Life
- Citigroup's China Plans Delayed by US Regulatory Issues: Report
- Tesla Model Y Could End Ford's Long Reign As America's Top-Selling Vehicle: Will 2024 Be The Year?
Latest Benzinga
- Evaluating TD Synnex: Insights From 7 Financial Analysts
- Here's How Much $100 Invested In Marathon Petroleum 10 Years Ago Would Be Worth Today
- Here's How Much $100 Invested In Marathon Petroleum 10 Years Ago Would Be Worth Today
- A Closer Look at 8 Analyst Recommendations For Crown Castle
- Citigroup's China Plans Delayed by US Regulatory Issues: Report
- Tesla Model Y Could End Ford's Long Reign As America's Top-Selling Vehicle: Will 2024 Be The Year?
- Tesla Model Y Could End Ford's Long Reign As America's Top-Selling Vehicle: Will 2024 Be The Year?
- Bitcoin's On-Chain Metrics Are Turning Bullish: What Is Going On?
- Bitcoin's On-Chain Metrics Are Turning Bullish: What Is Going On?
- Polymarket Traders Predict 45% Chance Of No Prison Time For Former FTX CEO Caroline Ellison